|
Author:
Date:
2016-11-20
[Abstract] Patient-derived xenograft (PDX) models for cancer research have recently attracted considerable attention in both the academy and industry (Hidalgo et al., 2014; Wilding and Bodmer, 2014). PDX models have been developed from different tumor types including lung cancer to improve the drug development process. These models are used for pre-clinical drug evaluation and can be used for the predictive results of clinical outcomes because they conserve original tumor characteristics such as heterogeneity, complexity and molecular diversity (Kopetz et al., 2012). Additionally, PDX model provides the potential tool for the personalized drug therapy. In this protocol, we present methods for the establishment of PDX in mice using primary tumor tissues from patients with small cell ...
[摘要] 用于癌症研究的患者衍生的异种移植（PDX）模型最近在学术和工业中引起了相当大的关注（Hidalgo等人，2014; Wilding和Bodmer，2014）。 PDX模型已经从不同的肿瘤类型开发，包括肺癌，以改善药物开发过程。 这些模型用于临床前药物评价，并且可用于临床结果的预测结果，因为它们保留原始肿瘤特征，例如异质性，复杂性和分子多样性（Kopetz等人，2012） 。 此外，PDX模型为个性化药物治疗提供了潜在的工具。 在该协议中，我们提出了使用来自小细胞肺癌（SCLC）患者的原发性肿瘤组织在小鼠中建立PDX的方法。
|